Agigma Inc.

Home

Technology

Market Opportunities

Products

Business Model

Team

 
 
Our technology enables transcutaneous delivery of large macromolecules, eliminating the need for chemical enhancement, injections or other invasive procedures.

FORMULATION FEATURES

Encapsulated (micronized or dissolved) API in Nanomatrix

Isolated control release polymer clusters

No water present in the final formulation

Self-dissolving skin patch system


PRE-CLINICAL DATA
In-vitro data obtained using Epiderm human skin model: demonstrated absorption and transcutaneous delivery of model biologics:
  • Enzyme 44 kDa
  • PA of Anthrax Toxin 83 kDa
  • PT of Pertusis Toxin 94 kDa
Macromolecules were stabilized in Nanomatrix without refridgeration; biological activity was fully preserved.


Efficacy, safety and compliance of dermatology products must be improved. Transdermal route must be expanded. Agigma fills a major product gap in these markets.